ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Christin Tse(Abbott Fund), Steven W. Elmore(AbbVie (United States)), Sha Jin(AbbVie (United States)), Xiao Yu(Huazhong Agricultural University), Lisa Roberts(Abbott Fund), Kennan C. Marsh(AbbVie (United States)), Mark G. Anderson(Abbott Fund), Jessica Adickes(Abbott Fund), Eric F. Johnson(Pfizer (United States)), Jun Chen(Jiangsu Normal University), Haichao Zhang(Abbott Fund), Xiufen Yang(Abbott Fund), Stephen K. Tahir(Abbott Fund), Alexander R. Shoemaker(Abbott Fund), Saul H. Rosenberg(Abbott Fund), Stephen W. Fesik(Vanderbilt University), Michael J. Mitten(Abbott Fund), Paul Nimmer(Abbott Fund)
Cited by 1,960
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
ABC transporters: the power to change
|Nature Reviews Molecular Cell Biology|2009|1.4k